Method of treating hypertension

Abstract

Disclosed herein are compositions and methods for the treatment of pulmonary hypertension, including pulmonary arterial hypertension. The methods include administering to a patient in need thereof an effective amount of anagrelide or derivative thereof. The compositions include an effective amount of anagrelide or derivative thereof, in some instances combined with one or more additional agents for the treatment of pulmonary hypertension.

1 - 21 . (canceled) 
     
     
         22 . A pharmaceutical composition comprising anagrelide or derivative thereof, in an amount effective to treat pulmonary arterial hypertension, and a further agent selected from the group consisting of a PDE-5 inhibitor, a calcium channel blocker, a prostacyclin pathway agonist, an endothelin receptor antagonist, a guanylate cyclase stimulator, an anti-coagulants, and combinations thereof. 
     
     
         23 . The pharmaceutical composition according to  claim 22 , wherein the further agent comprises a PDE-5 inhibitor comprising avanafil, lodenafil, mirodenafil, sildenafil, tadalafil, vardenafil, udenafil, zaprinast, or icariin. 
     
     
         24 . The pharmaceutical composition according to  claim 22 , wherein the further agent comprises a calcium channel blocker comprising amlodipine, nifefipine, or diltiazem. 
     
     
         25 . The pharmaceutical composition according to  claim 22 , wherein the further agent comprises a prostacyclin pathway agonist comprising epoprostenol, treprostinil, iloprost, or selexipag. 
     
     
         26 . The pharmaceutical composition according to  claim 22 , wherein the further agent comprises an endothelin receptor antagonist comprising bosentan, macitentan, ambrisentan, or sitaxsentan. 
     
     
         27 . The pharmaceutical composition according to  claim 22 , wherein the further agent comprises a guanylate cyclase stimulator. 
     
     
         28 . The pharmaceutical composition according to  claim 22 , wherein the further agent comprises an anti-coagulant. 
     
     
         29 . A kit comprising a pharmaceutical composition comprising anagrelide or derivative thereof, in an amount effective to treat pulmonary arterial hypertension, and a further agent selected from the group consisting of a PDE-5 inhibitor, a calcium channel blocker, a prostacyclin pathway agonist, an endothelin receptor antagonist, a guanylate cyclase stimulator, an anti-coagulants, and combinations thereof. 
     
     
         30 . The kit according to  claim 29 , wherein the further agent is provided in a separate composition from the anagrelide. 
     
     
         31 . The kit according to  claim 29 , wherein the further agent comprises a PDE-5 inhibitor comprising avanafil, lodenafil, mirodenafil, sildenafil, tadalafil, vardenafil, udenafil, zaprinast, or icariin. 
     
     
         32 . The kit according to  claim 29 , wherein the further agent comprises a calcium channel blocker comprising amlodipine, nifefipine, or diltiazem. 
     
     
         33 . The kit according to  claim 29 , wherein the further agent comprises a prostacyclin pathway agonist comprising epoprostenol, treprostinil, iloprost, or selexipag. 
     
     
         34 . The kit according to  claim 29 , wherein the further agent comprises an endothelin receptor antagonist comprising bosentan, macitentan, ambrisentan, or sitaxsentan. 
     
     
         35 . The kit according to  claim 29 , wherein the further agent comprises a guanylate cyclase stimulator. 
     
     
         36 . The kit according to  claim 29 , wherein the further agent comprises an anti-coagulant.